Healthcare · Pharmaceuticals
The Pharma GAAP Payout Trap
Why Pfizer's ~126% and AbbVie's ~276% GAAP payout ratios mislead: non-cash charges on acquired assets, and how to test pharma dividends against cash.
Selborne Research · Pharmaceuticals coverage: 7 guides, 6 company profiles, a primer and Excel model
Educational analysis for professional use. This guide is not investment advice or a recommendation to buy or sell any security, and it is not personalised.
On this page
GAAP Payout Can Exceed 100% While Cash Still Covers the Dividend
Income investors usually start with dividends divided by GAAP net income. At drugmakers that grow by acquisition the ratio breaks: Pfizer’s FY2025 GAAP payout was ~126% and AbbVie’s ~276%, and neither says much about cash.
GAAP net income is struck after amortisation of acquired intangibles, write-downs of acquired assets and changes in what is owed on past deals. None of these uses cash in the year. So a drugmaker can show a triple-digit GAAP payout while its dividend takes well under its operating cash flow.
FY2025 GAAP Payout, Six Filers
| Company | Dividend / share | GAAP payout | What drives the ratio |
|---|---|---|---|
| Eli Lilly | $6.00 | 26.1% | Fast-growing earnings |
| Merck | $3.24 | 44.5% | No large distortion noted |
| Johnson & Johnson | $5.14 | ~46.2% | Net income lifted by a ~$7.0B talc reserve reversal |
| Novo Nordisk | DKK 11.70 | 50.7% | No large distortion noted |
| Pfizer | $1.72 | ~126% | Amortisation, impairments, restructuring |
| AbbVie | $6.65 | ~276% | Amortisation, contingent consideration charge |
Lilly’s ratio is low because earnings grew faster than the dividend. Its 26.1% ($6.00 ÷ diluted EPS of $22.95) reflects profit lifted by tirzepatide, its diabetes and weight-loss drug, even after spending 20.5% of sales on R&D. JNJ’s ~46.2% ($12,381M dividends ÷ $26,804M GAAP net income) sits close to Merck’s 44.5%, but a one-off gain lifted the net income it divides by (covered below).
Worked Example: AbbVie GAAP vs Cash Story
AbbVie FY2025 (Form 10-K):
| Item | Amount |
|---|---|
| Net revenue | $61,160M |
| Amortisation of acquired intangibles (inside cost of products sold) | $7,377M |
| GAAP operating earnings | $15,075M (24.6% margin) |
| Interest expense, net | $2,627M |
| Other expense, net (incl. $6.5B contingent consideration charge) | $5,793M |
| Foreign exchange loss | $58M |
| Income tax | $2,364M |
| Earnings to minority interests | $7M |
| GAAP net earnings | $4,226M |
| Dividends paid | $11,657M |
| GAAP payout | $11,657M ÷ $4,226M = ~276% |
| Operating cash flow | $19,030M |
| Dividends ÷ operating cash flow | ~61% |
| Capital expenditure | $1,214M |
| Free cash flow (operating cash flow − capital expenditure) | $17,816M |
| Dividends ÷ free cash flow | ~65% |
The distortion enters twice. Amortisation of acquired intangibles ($7,377M) sits inside cost of products sold, so it lowers operating earnings. Below that line, other expense includes a $6.5B charge for the rise in fair value of contingent consideration: payments AbbVie may owe the sellers of businesses it bought. Neither charge used cash in the year. That is most of why operating cash flow of $19,030M was more than four times net earnings, and why the $6.65/share dividend took only about 61% of it, or about 65% of free cash flow after $1,214M of capital spending.
The product mix shows who now pays the dividend. Humira, the arthritis drug that lost US exclusivity in 2023 to biosimilars (near-copies of a biologic drug made by rival manufacturers), fell to $4,540M (7.4% of revenue). Two newer immunology drugs, Skyrizi (28.7%) and Rinvoq (13.6%), now carry it. Dividend cover depends on the cash those two generate and on concentration.
Pfizer: Write-Downs in the Denominator
Pfizer FY2025:
| Item | Amount |
|---|---|
| Revenue | $62,579M |
| Amortisation of intangible assets | $4,874M |
| Restructuring and acquisition-related costs | $1,550M |
| Operating income (computed, after both) | $14,244M (22.8% margin) |
| Asset impairments (in other deductions) | $4,940M |
| Interest, other items and tax, net (computed) | $1,533M |
| GAAP net income | $7,771M |
| Dividends paid | $9,771M |
| GAAP payout | ~126% |
| Operating cash flow | $11,704M |
| Dividends ÷ operating cash flow | ~83% |
| Capital expenditure | $2,629M |
| Free cash flow (operating cash flow − capital expenditure) | $9,075M |
| Dividends ÷ free cash flow | ~108% |
Amortisation, impairments and restructuring together came to $11,364M, more than GAAP net income itself. Pfizer’s risk isn’t one drug: Eliquis, a blood thinner and its largest product, is only 12.7% of revenue (see concentration). On cash, dividends took about 83% of operating cash flow, against about 61% at AbbVie. After $2,629M of capital spending, free cash flow was $9,075M, less than the $9,771M paid out in dividends.
Pfizer expects to lose roughly $1.5B of revenue in 2026 (~2.4% of FY2025 revenue) as drugs lose patent protection, known as loss of exclusivity (LOE). Test the dividend against free cash flow after those losses. See Pfizer.
Johnson & Johnson: GAAP Distortion in the Other Direction
JNJ’s FY2025 GAAP payout of ~46.2% ($12,381M ÷ $26,804M) is close to Merck’s 44.5%, but the net income it divides by carries a one-off gain. J&J had set money aside, a reserve, for the expected cost of settling lawsuits over its talc products. When a Texas court dismissed the bankruptcy case meant to deliver that settlement in March 2025, J&J reversed about $7.0B of the reserve, and the reversal counted as income. It sat inside other income of $7,209M and lifted pre-tax earnings to $32,581M.
| Item | Amount |
|---|---|
| GAAP net income | $26,804M |
| Talc reserve reversal (pre-tax, inside other income) | ~$7,000M |
| Dividends paid | $12,381M |
| GAAP payout | ~46.2% |
| Payout with the reversal removed | $12,381M ÷ ($26,804M − $7,000M) = ~62.5% |
| Operating cash flow | $24,530M |
| Dividends ÷ operating cash flow | ~50% |
| Capital expenditure | $4,832M |
| Free cash flow (operating cash flow − capital expenditure) | $19,698M |
| Dividends ÷ free cash flow | ~63% |
The 62.5% takes the full pre-tax $7.0B out of after-tax net income, with no allowance for tax on the gain, so it is the upper end of the adjusted payout. The reversal used no cash, which is why the cash ratios are unaffected by it.
See Johnson & Johnson.
How to Screen Pharma Dividends Without the Trap
- Start with cash: dividends paid ÷ operating cash flow, then ÷ free cash flow after capital spending.
- Read the GAAP-to-adjusted reconciliation in the earnings release to see which charges and gains moved the ratio.
- Date the patent cliffs on the top products from the patent expiry calendar. A 45% payout says little about the years after a cliff. At Merck, Keytruda is 48.7% of sales and faces LOE within three years.
- Expect growing companies to pay out less, because profit rising faster than the dividend pulls the ratio down: Lilly’s 26.1% came from earnings lifted by tirzepatide, even with 20.5% of sales going to R&D.
- Value the pipeline with risk-adjusted NPV (rNPV), which weights each drug in development by its odds of approval, to test whether new drugs can carry the dividend after the cliff years.
Payouts of ~126% and ~276% are prompts to open the cash flow statement and the footnotes.
A base business, a drug at its patent cliff, a growing biologic and a Phase III asset, each valued year by year and summed to value per share.
- 15 sections, the patent ladder to a year-by-year sum-of-parts valuation and concentration screens
- 39 pages
- a small molecule at its cliff, a biologic growth driver and a pipeline asset weighted by its phase, plus a base business
- 3 drug schedules
- large-cap innovators on filed product concentration and loss-of-exclusivity dates
- 6-company screen
The Excel model is the primer's sum-of-parts valuation live across 13 sheets: a base-business DCF at an 8.5% WACC; three drug schedules, each set to marketed or pipeline and to a clinical phase that sets its odds; loss-of-exclusivity cliffs that settle on a generic floor; a calendar-year input that turns a filed patent date into a schedule year; the consolidated bridge to value per share; and patent-cliff, concentration and sensitivity views. Change a drug's LOE year, phase or peak sales, or the WACC, and the value moves.
See what's in the Pharmaceuticals Sector Primer →£25 PDF · £59 with the Excel model · £159 for all three Healthcare industries
Frequently Asked Questions
- What payout ratios do large pharma companies report?
- On FY2025 GAAP net income: Eli Lilly 26.1%, Merck 44.5%, Johnson & Johnson ~46.2%, Novo Nordisk 50.7%, Pfizer ~126% and AbbVie ~276%. The last two are distorted by non-cash charges. Measured against operating cash flow the dividend took about 83% at Pfizer, 61% at AbbVie and 50% at Johnson & Johnson; against free cash flow, after capital spending, about 108%, 65% and 63%.
- Why is Pfizer's dividend payout ratio above 100%?
- Pfizer's FY2025 GAAP payout was ~126% ($9,771M dividends paid ÷ $7,771M GAAP net income). Three charges that used little or no cash in the year sat between revenue and net income: $4,874M of amortisation on acquired intangibles, $4,940M of asset impairments and $1,550M of restructuring and acquisition-related costs. Dividends took about 83% of the $11,704M operating cash flow.
- Why does AbbVie show ~276% GAAP payout?
- AbbVie paid $11,657M in dividends against $4,226M GAAP net earnings in FY2025 (~276% payout). Two non-cash charges explain most of the gap: $7,377M of amortisation on acquired intangibles, and a $6.5B charge for the change in fair value of contingent consideration owed on past acquisitions. Operating cash flow was $19,030M, so dividends took about 61% of it.
- Should you screen pharma dividends on GAAP payout ratio?
- No, not without adjustment. Deal-driven amortisation, write-downs and one-time items distort GAAP net income in both directions: down at Pfizer and AbbVie, up at Johnson & Johnson in FY2025. Use adjusted EPS, free cash flow payout, or net debt metrics alongside GAAP payout. Pair it with concentration and loss-of-exclusivity (LOE) analysis so dividend cover survives the years when big drugs lose patent protection.
Read next
Pharma Revenue Concentration Risk
Largest-product revenue share as a risk screen: FY2025 ladder from Pfizer Eliquis 12.7% to Lilly tirzepatide 56.0%, with 25–30% and 40% concentration screens.
rNPV: Valuing Drug Pipelines
Risk-adjusted NPV for drug pipelines: PoS-weighted cash flows, an 8.5% WACC built on a 4.50% 10-year Treasury rate, and a worked Phase III asset at $1,621M.
GAAP vs Adjusted Operating Margin in Medtech
What device makers leave out of adjusted operating margin: amortisation from past deals, restructuring, litigation and share-based pay, how six filers define adjusted, and which margin a DCF should carry.
See it applied
These company profiles apply the concepts from this guide to real public companies.